未知股票 DBV 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 30.00万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 0.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies, a clinical-stage biopharmaceutical company, has announced the establishment of an at-the-market (ATM) program on the Nasdaq Capital Market, allowing it to offer and sell up to $150 million in American Depositary Shares (ADS). The proceeds will primarily support activities related to the Biologics License Application (BLA) for VIASKIN® Peanut patch in toddlers aged 1-3 years, as well as advance the development of other product ca...
2025-09-05 20:30
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will be webcast live and available on the Company’s Investors website for 90 days. DBV is developing the VIASKIN® patch for treating food allergies through epicutaneous immunotherapy, targeting millions affected by this condition. The company focuses on clinical trials...
2025-09-03 20:30
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
DBV Technologies reported its Q2 2025 financial results, showing a net loss of $69.0 million for the first half of the year, compared to $60.5 million in 2024. Operating income decreased by $2.2 million due to reduced French research tax credits, while operating expenses rose by 7.5% due to increased R&D activities. The company raised $306.9 million in financing to advance its Viaskin Peanut patch, with $125.5 million received in April 2025. Cas...
2025-07-29 20:08
DBV Technologies to Participate in Upcoming EAACI Congress 2025
DBV Technologies will participate in the EAACI Congress 2025 in Glasgow, presenting two posters, hosting a symposium, and exhibiting. They will share data on reduced accidental peanut reaction rates in Year 2 of the EPITOPE trial and results from the APTITUDE study on diagnosing non-IgE-mediated cow’s milk allergy. The symposium, "Peanut Allergy: Recent Research Highlights," will discuss epicutaneous immunotherapy and the allergist-patient relati...
2025-06-12 20:05
重磅！美国PTP相关证券10%预扣税即将开征，哪些标的或受影响？
从2023年1月1日起，美国国税局和财政部将针对非美国人投资PTP（Public Traded Partnership，公开交易合伙企业）股票或ETF等相关证券，按交易总金额10%扣缴预扣税。
2022-11-22 20:45
